NCT01515176View on ClinicalTrials.gov

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 4, 2015

Study Completion Date

July 19, 2016

Conditions
Chronic Lymphocytic LeukemiaProlymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
Interventions
DRUG

Dinaciclib

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Ofatumumab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01515176 - Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | Biotech Hunter | Biotech Hunter